Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Prothena Corporation plc (PRTA : NSDQ)
 
 • Company Description   
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.

Number of Employees: 163

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.22 Daily Weekly Monthly
20 Day Moving Average: 1,431,144 shares
Shares Outstanding: 53.83 (millions)
Market Capitalization: $334.80 (millions)
Beta: 0.01
52 Week High: $25.42
52 Week Low: $4.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.12% 4.56%
12 Week -34.80% -44.78%
Year To Date -55.09% -57.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS
-
DUBLIN,L2 D02 VK60
IRL
ph: 011-353-1236-2500
fax: 353-1902-3510
mark.johnson@prothena.com http://www.prothena.com
 
 • General Corporate Information   
Officers
Gene G. Kinney - Chief Executive Officer and President
Daniel G. Welch - Chair of the Board
Tran B. Nguyen - Chief Financial Officer
Paula K. Cobb - Director
Richard T. Collier - Director

Peer Information
Prothena Corporation plc (CORR.)
Prothena Corporation plc (RSPI)
Prothena Corporation plc (CGXP)
Prothena Corporation plc (BGEN)
Prothena Corporation plc (GTBP)
Prothena Corporation plc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G72800108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 53.83
Most Recent Split Date: (:1)
Beta: 0.01
Market Capitalization: $334.80 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.76
Price/Cash Flow: -
Price / Sales: 2.43
EPS Growth
vs. Year Ago Period: 16.42%
vs. Previous Quarter: -3.70%
Sales Growth
vs. Year Ago Period: 5,556.00%
vs. Previous Quarter: 33.21%
ROE
06/30/25 - -
03/31/25 - -21.61
12/31/24 - -23.24
ROA
06/30/25 - -
03/31/25 - -19.32
12/31/24 - -20.29
Current Ratio
06/30/25 - -
03/31/25 - 9.00
12/31/24 - 10.01
Quick Ratio
06/30/25 - -
03/31/25 - 9.00
12/31/24 - 10.01
Operating Margin
06/30/25 - -
03/31/25 - -79.94
12/31/24 - -90.50
Net Margin
06/30/25 - -
03/31/25 - -79.94
12/31/24 - -90.50
Pre-Tax Margin
06/30/25 - -
03/31/25 - -84.00
12/31/24 - -95.39
Book Value
06/30/25 - -
03/31/25 - 8.13
12/31/24 - 9.05
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©